AI Article Synopsis
- Paxlovid received emergency approval in China for COVID-19 treatment, but its effects on kidney transplant patients taking tacrolimus are not well-studied.
- Tacrolimus was stopped on the same day Paxlovid was administered, with close monitoring of tacrolimus and creatinine levels using EMIT and LC-MS/MS techniques.
- The study found that creatinine levels increased in three patients, and that EMIT might give higher readings of tacrolimus metabolites than LC-MS/MS; all findings followed ethical guidelines.
Article Abstract
Paxlovid, as a new drug, received emergency approval for the treatment of COVID-19 in China; there is very little experience with kidney transplantation patients taking tacrolimus with perioperative COVID-19 infection. We discontinued tacrolimus on the day of using Paxlovid, and we chose to frequently monitor the concentration of tacrolimus and creatinine early in the course of treatment by enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-mass spectrometry (LC-MS/MS). The results show varying degrees of elevation of creatinine levels in 3 patients, and EMIT may overestimate the true concentration of tacrolimus metabolites compared with LC-MS/MS. All the data comply with the Helsinki Congress and the Declaration of Istanbul.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.transproceed.2023.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!